Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis 2023-04-13 06:00
Standigm announces Younsung Choo as chief executive officer 2023-04-13 00:07
Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and Southeast Asia 2023-04-12 06:00
Lunit Demonstrates Progress in the Development of Novel Diagnostics at the 2023 AACR Annual Meeting 2023-04-11 21:00
OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023 2023-04-11 20:00
SK Biopharmaceuticals Wins Red Dot Design Award for Wearable Devices 2023-04-11 08:00
Asieris' subsidiary makes significant progress in its commercialization strategy by obtaining the "Drug Distribution License" 2023-04-10 20:18
GC Genome Announces Publication Demonstrating Feasibility of Liquid Biopsy Technology to Predict Radiation Therapy Response in Solid Tumors 2023-04-10 11:39
China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released 2023-04-07 16:34
Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD") 2023-04-07 10:00
AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering 2023-04-07 07:15
Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio 2023-04-06 10:20
BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer 2023-04-05 20:00
Standigm and Institut Pasteur Korea Identify Lead Compounds for Resistant Tuberculosis Thanks to Right Foundation Grant 2023-04-05 00:07
Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis 2023-04-04 20:50
Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects 2023-04-04 20:00
iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model. 2023-04-04 10:33
GC Cell and New Management Embarking on a New Chapter 2023-04-03 16:47
Harbour BioMed Reports Full Year 2022 Financial Results 2023-04-03 15:10
The World's Second Approved Biosimilars of Denosumab (MAILISHU) 2023-04-03 13:44
1 85 86 87 88 89 431